Endovascular Treatment for Acute Large Vessel Occlusion With Ultra-Large Ischemic Core

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: NA

Enrollment: 450

Sponsor: First Affiliated Hospital of Harbin Medical University

Location: he First Affiliated Hospital of Harbin Medical University Harbin Hei Longjiang

Summary

an investigator initiated, prospective, multicenter, randomized, open-label, blinded endpoint trial (PROBE)

Eligibility Criteria

Inclusion Criteria: 1. ≥18 years. 2. Symptoms onset or Time last known well ≤ 24 h from randomization. 3. Acute ischemic stroke due to an occlusion of the intracranial internal carotid artery, M1 or proximal M2 segment of the middle cerebral artery confirmed by CTA or MRA. 4. NCCT or diffusion-weighted imaging (DWI) demonstrating ASPECTS ≤ 2 or infarct core volume (defined as rCBF \185/110 mmHg and is refractory to medicine. 5. Known coagulopathy, with international normalized ratio (INR) \>1.7 or platelet count \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07791810). StuddyBuddy aggregates publicly available trial information.